Post by Takeda

We're excited to connect with neurologists and the neuroscience community at the American Academy of Neurology (AAN) 2026 Annual Meeting. #Narcolepsy type 1 (NT1) is a serious neurological condition with a broad range of complex—and often overlooked—symptoms that can significantly impact daily life, work and independence. Takeda will be presenting encore data from FirstLight and RadiantLight, two global Phase 3 studies that explored an investigational approach for NT1. If you’re attending, visit the Takeda booth # 3625. In the meantime, you can learn more about Takeda’s commitment to neuroscience and orexin science here: https://lnkd.in/eAUzKv6s. #AANAM #Neurology [For U.S. healthcare professionals only]